Compare MNSO & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNSO | TVTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.3B |
| IPO Year | 2020 | 2013 |
| Metric | MNSO | TVTX |
|---|---|---|
| Price | $11.73 | $56.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $26.20 | ★ $40.62 |
| AVG Volume (30 Days) | 670.1K | ★ 2.2M |
| Earning Date | 05-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.09 | $44.76 |
| Revenue Next Year | $15.43 | $35.51 |
| P/E Ratio | $20.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.12 | $15.03 |
| 52 Week High | $26.74 | $60.10 |
| Indicator | MNSO | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 67.02 |
| Support Level | N/A | $41.75 |
| Resistance Level | $20.11 | $60.10 |
| Average True Range (ATR) | 0.31 | 2.09 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 26.09 | 71.40 |
MINISO Group Holding Ltd is a value retailer offering a variety of trendy lifestyle products featuring IP design. The principal activity of the Company is investment holding. The company's product categories include home decor, small electronics, textiles, accessories, beauty tools, toys, cosmetics, personal care, snacks, fragrance and perfumes, and stationery and gifts. Its segment includes the MINISO brand -Chinese Mainland and MINISO brand-Overseas which is engaged in the Design, buying, and sale of lifestyle products, and the TOP TOY brand, which is engaged in the Design, buying, and sale of pop toys. The company generates maximum revenue from theMINISO brand -Chinese Mainland segment. Geographically, it derives a majority of its revenue from Chinese Mainland.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.